Sexual desire research in premenopausal women
In a randomized trial, 32 premenopausal women with distressing low sexual desire completed visits with kisspeptin-54 and with placebo. The study found changes in brain responses to sexual and attraction cues during the visit. Longer studies would be needed to establish sustained improvement in everyday sexual desire or distress.
Sources for this section
Egg-maturation research during IVF
A phase 2 study tested kisspeptin-54 as a trigger for final egg maturation before retrieval in 60 patients at high risk of an excessive response to ovarian stimulation. The study assessed egg maturation in a monitored IVF cycle. It leaves open how the approach compares with standard triggers for live births in broader patient groups.
Sources for this section
What the FDA says about kisspeptin-10
Kisspeptin-10 is a shorter peptide than the kisspeptin-54 used in these two studies. FDA identifies possible safety risks with compounded kisspeptin-10, including immune reactions and difficulties assessing impurities. The findings above apply to the form and settings the studies actually used.